Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00799617 · ClinicalTrials.gov registry record · Phase 3
The Testosterone Trials in Older Men
A Phase 3 study of Andropause, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 3
- Development phase
- 790
- Enrollment target
- 12
- Study locations
NCT00799617 is a Phase 3 study of Andropause that has completed, run by University of Pennsylvania. The registered enrollment target is 790 participants. The trial reports 12 study locations across 11 states.
The verdict
NCT00799617, a Phase 3 study of Andropause, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 790 participants
- Enrollment target
- 12
- Study locations
Study Summary
The Testosterone Trials are a multi-center set of trials involving 12 clinical sites geographically distributed across the United States. The primary specific aims are to test the hypotheses that testosterone treatment of elderly men whose serum testosterone concentrations are unequivocally low - and who have symptoms and objectively measured abnormalities in at least one of five areas that could be due to low testosterone (physical or sexual function, vitality, cognition, and anemia) - will result in more favorable changes in those abnormalities than placebo treatment. Two additional trials have been incorporated into the T Trial. Only men enrolled in the T Trial are eligible to participate in these trials. * The Cardiovascular Trial will examine if testosterone treatment results in more favorable changes in cardiovascular risk factors, compared to placebo. * The Bone Trial will test the hypothesis that testosterone treatment will increase volumetric trabecular bone mineral density (vBMD) of the lumbar spine as measured by quantitative computed tomography (QCT), compared with placebo treatment. A Pharmacokinetic (PK) Study is also being conducted within the context of the interventional T Trial. It will examine the variability of the serum testosterone (T) concentration after application of testosterone gel or placebo, four months after the start of treatment.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AndroGel® (testosterone gel)
Study Locations (12)
California
- University of California San Diego - La Jolla
- Center for Men's Health LA BioMed at Harbor-UCLA Medical Center - Torrance
Alabama
- University of Alabama at Birmingham - Birmingham
Connecticut
- Yale University - New Haven
Florida
- University of Florida - Gainesville
Illinois
- Northwestern University - Chicago
Massachusetts
- Boston University - Boston
Minnesota
- University of Minnesota - Minneapolis
New York
- Albert Einstein College of Medicine - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 790 participants |
| Start Date | 2009-11 |
| Est. Completion | 2018-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00799617
The ClinicalTrials.gov registry entry for NCT00799617 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 790 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Andropause appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00799617 reports 12 study locations spanning 11 distinct geographic areas - top geographies include California, Alabama, Connecticut.
Frequently Asked Questions
What is clinical trial NCT00799617 about?
NCT00799617 is a clinical study titled "The Testosterone Trials in Older Men". The Testosterone Trials are a multi-center set of trials involving 12 clinical sites geographically distributed across the United States. The primary specific aims are to test the hypotheses that testosterone treatment of elderly men whose serum testosterone concentrations are unequivocally low - a...
What is the current status of trial NCT00799617?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 790 participants. The study started on 2009-11. Estimated completion is 2018-12.
What conditions does trial NCT00799617 study?
This clinical trial studies the following conditions: Andropause.
What interventions are being tested in trial NCT00799617?
The interventions under investigation include: Placebo (DRUG), AndroGel® (testosterone gel) (DRUG).
Who is sponsoring clinical trial NCT00799617?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00799617 being conducted?
This trial has 12 study locations across Alabama, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.